Shidong Luo
YOU?
Author Swipe
View article: Data from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i>
Data from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i> Open
Anti-epidermal growth factor receptor (EGFR) treatment has been successfully applied in clinical cancer therapy. However, the clinical efficacy of first-generation reversible EGFR inhibitors, such as gefitinib and erlotinib, is limited by …
View article: Supplementary Methods, Tables 1-4, Figures 1-4 from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Methods, Tables 1-4, Figures 1-4 from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 466K
View article: Supplementary Methods, Tables 1-4, Figures 1-4 from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Methods, Tables 1-4, Figures 1-4 from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 466K
View article: Data from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i>
Data from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i> Open
Anti-epidermal growth factor receptor (EGFR) treatment has been successfully applied in clinical cancer therapy. However, the clinical efficacy of first-generation reversible EGFR inhibitors, such as gefitinib and erlotinib, is limited by …